Dr. Rajul Jain is a Managing Director of Vida Ventures where he is focused on the creation and development of biotechnology and pharmaceutical companies. He joined Vida in 2019 as a Director, and has played a significant role in the growth and value creation of Vida’s life sciences portfolio, both in the investor capacity and as an investor-operator. In addition to being a director of LB Pharma, Dr. Jain is currently a director of Capstan Therapeutics, where he was previously the interim CMO, and InduPro. He was previously a director of Neogene Therapeutics, where he was also the acting CMO at the time of its acquisition by Astra Zeneca, and Quanta Therapeutics, as well as others. Prior to joining Vida, he was at Kite Pharma which was acquired by Gilead for $11.9B. He. joined Kite when it was a preclinical stage company, and ultimately in his last role as VP of Clinical Development and CMO, led a 200-person organization overseeing the development of multiple engineered cell therapies from preclinical development through global regulatory approvals, including approvals for Yescarta and Tecartus. Previously, he was at Amgen where his last role was Global Development Lead. There he oversaw the development of small molecules and biologics in the oncology and bone health therapeutic areas and was instrumental in advancing the R&D pipeline including securing regulatory approvals of Xgeva and Prolia. Dr. Jain completed his BA in chemistry and biochemistry at Rice University, and M.D. and Internal Medicine internship and residency at UT Southwestern Medical school, where he was a Howard Hughes Fellow. He completed his post-doctoral training in biophysics at Rockefeller University, and fellowship training at MD Anderson Cancer Center, where he was Chief Fellow. He was previously a volunteer Attending Physician treating underserved patients at UCLA Harbor Medical Center and continues to lecture regularly at UCLA.
